Olivera Finn | Academic Influence

Olivera Finn's AcademicInfluence.com Rankings

Olivera Finn

Biology

#6388

World Rank

#9088

Historical Rank

Immunology

#360

World Rank

#374

Historical Rank

biology Degrees

Download Badge

Biology

Olivera Finn's Degrees

Bachelors Biology University of Belgrade

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Olivera Finn Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Olivera J. Finn is a Yugoslav-American immunologist who is a distinguished professor and former chair of the department of immunology at the University of Pittsburgh and former director of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute . She was president of the American Association of Immunologists from 2007 to 2008 and served on the AAI Council from 2002 to 2006.

(See a Problem?)

Olivera Finn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research (2009) (1171)
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. (2001) (888)
Cancer immunology. (2011) (625)
Cancer vaccines: between the idea and the reality (2003) (608)
Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. (2012) (511)
Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. (1989) (474)
Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. (1991) (393)
Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. (1994) (338)
A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. (1996) (271)
MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines (1995) (267)
Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-I cDNA (1988) (263)
Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. (1993) (247)
Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin (1997) (226)
MUC1 immunobiology: from discovery to clinical applications. (2004) (224)
MCF7 Side Population (SP) cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1 (2008) (219)
MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study (2012) (210)
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. (2008) (199)
Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. (1993) (197)
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer (2005) (183)
The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells1 (2000) (176)
IL‐33 synergizes with TCR and IL‐12 signaling to promote the effector function of CD8+ T cells (2011) (176)
Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. (1995) (170)
Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic Cells (2002) (165)
Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. (1984) (161)
Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection1 (2001) (146)
The dawn of vaccines for cancer prevention (2017) (143)
Conditions Associated with Antibodies Against the Tumor-Associated Antigen MUC1 and Their Relationship to Risk for Ovarian Cancer (2005) (139)
Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). (1996) (134)
Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells (2001) (132)
Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2. (1985) (121)
Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. (1988) (119)
In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. (1997) (112)
Establishment, characterization and virus expression of cell lines derived from radiation‐ and virus‐induced lymphomas of C57BL/Ka mice (1979) (104)
T Cell–Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease (2005) (102)
Precancer Atlas to Drive Precision Prevention Trials. (2017) (98)
Human Tumor Antigen MUC1 Is Chemotactic for Immature Dendritic Cells and Elicits Maturation but Does Not Promote Th1 Type Immunity 1 (2005) (98)
T-cell death and cancer immune tolerance (2008) (98)
Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. (1999) (96)
Human tumor antigens are ready to fly. (1996) (93)
MUC1 and other sialoglycoconjugates inhibit adenovirus-mediated gene transfer to epithelial cells. (1997) (93)
A Believer’s Overview of Cancer Immunosurveillance and Immunotherapy (2018) (91)
Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. (1998) (90)
Immune response as a biomarker for cancer detection and a lot more. (2005) (89)
Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. (2006) (86)
MUC1 immunotherapy is here to stay (2013) (86)
Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope. (1995) (85)
Cancer immunology. (2008) (84)
Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. (2002) (79)
T cell receptor beta-chain selection in human allograft rejection. (1989) (79)
Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T‐cell migration (2003) (78)
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines☆ (2017) (77)
Epidemiologic perspective on immune-surveillance in cancer. (2011) (75)
mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting (2017) (74)
Cutting Edge: Transgenic Expression of Human MUC1 in IL-10−/− Mice Accelerates Inflammatory Bowel Disease and Progression to Colon Cancer1 (2007) (73)
Vaccine against MUC1 Antigen Expressed in Inflammatory Bowel Disease and Cancer Lessens Colonic Inflammation and Prevents Progression to Colitis-Associated Colon Cancer (2010) (71)
Prophylactic cancer vaccines. (2002) (70)
Incessant Ovulation, Mucin 1 Immunity, and Risk for Ovarian Cancer (2007) (70)
Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. (2001) (69)
O‐Linked glycans control glycoprotein processing by antigen‐presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells (2003) (68)
Rapid, comprehensive analysis of human cytokine mRNA and its application to the study of acute renal allograft rejection. (1995) (67)
Inflammation Driven by Overexpression of the Hypoglycosylated Abnormal Mucin 1 (MUC1) Links Inflammatory Bowel Disease and Pancreatitis (2010) (64)
MUC1 Protein Expression in Tumor Cells Regulates Transcription of Proinflammatory Cytokines by Forming a Complex with Nuclear Factor-κB p65 and Binding to Cytokine Promoters (2011) (63)
Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: Potential role in metastasis (2004) (63)
Human Tumor Antigens Yesterday, Today, and Tomorrow (2017) (61)
Vaccines for Cancer Prevention: A Practical and Feasible Approach to the Cancer Epidemic (2014) (60)
Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles (2010) (59)
Autoantigens act as tissue‐specific chemoattractants (2005) (58)
Carbohydrate Recognition on MUC1‐Expressing Targets Enhances Cytotoxicity of a T Cell Subpopulation (1997) (57)
Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer (2019) (57)
Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. (1996) (56)
PCR-based analysis of the T-cell receptor V beta multigene family: experimental parameters affecting its validity. (1992) (56)
Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. (2010) (55)
Increased expression of glycolysis‐associated genes in oncogene‐transformed and growth‐accelerated states (1989) (55)
Premalignant Lesions as Targets for Cancer Vaccines (2003) (54)
Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. (1998) (54)
Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer (2009) (52)
Colorectal cancer prevention: Immune modulation taking the stage. (2018) (51)
Human tumor antigens, immunosurveillance, and cancer vaccines (2006) (51)
Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. (1999) (51)
Cancer vaccines: accomplishments and challenges. (2008) (51)
Tumor-rejection antigens recognized by T lymphocytes. (1993) (50)
Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. (2009) (50)
Tumor antigens and tumor antigen discovery. (2005) (50)
Lack of Effective MUC1 Tumor Antigen-Specific Immunity in MUC1-Transgenic Mice Results from a Th/T Regulatory Cell Imbalance That Can Be Corrected by Adoptive Transfer of Wild-Type Th Cells1 (2007) (49)
Renal allograft-infiltrating lymphocytes. A prospective analysis of in vitro growth characteristics and clinical relevance. (1992) (49)
Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice (2009) (49)
Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms (2013) (48)
Cancer immunoprevention. (2016) (48)
Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic (2011) (48)
Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies (2010) (47)
Beneficial autoimmunity improves cancer prognosis (2021) (47)
Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. (2005) (46)
Expression of tumor-associated epitopes on Epstein-Barr virus-immortalized B-cells and Burkitt's lymphomas transfected with epithelial mucin complementary DNA. (1992) (46)
Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer (2016) (46)
Mumps and ovarian cancer: modern interpretation of an historic association (2010) (44)
Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas (2011) (42)
Biology, biochemistry and immunology of carcinoma-associated mucins. (1997) (42)
Chimpanzee dendritic cells with potent immunostimulatory function can be propagated from peripheral blood (1996) (39)
Specific and Effective T‐Cell Recognition of Cells Transfected with a Truncated Human Mucin cDNA (1993) (38)
PROPHYLACTIC CANCER VACCINES (2002) (38)
Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name. (2018) (37)
Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and Metastasis (2016) (37)
Aberrant Expression of MUC1 Mucin in Pediatric Inflammatory Bowel Disease (2010) (37)
Glycoprotein tumor antigens for immunotherapy of breast cancer. (2004) (36)
Human tumor-specific cytotoxic T cell lines generated from tumor-draining lymph node infiltrate. (1988) (35)
A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis (1997) (34)
Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration (2013) (33)
AACR Cancer Progress Report 2012 (2012) (33)
Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer (2019) (32)
MCF 7 Side Population Cells with Characteristics of Cancer Stem / Progenitor Cells Express the Tumor Antigen MUC 1 (2008) (32)
Recent advances in cellular immunology: implications for immunity to cancer. (1990) (32)
Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. (2010) (32)
DNA vaccines for cancer too (2006) (31)
Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential (2016) (30)
Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells (2006) (30)
Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. (1998) (28)
Recombinant vaccinia mucin vector: in vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T-cell recognition. (1993) (28)
T cell receptor V beta gene usage in allograft-derived cell lines analyzed by a polymerase chain reaction technique. (1992) (28)
Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. (2009) (27)
Tumor Antigen-Based Immunotherapy and Immunoprevention of Cancer (2006) (27)
Characterization of T cells expressing the γ/δ antigen receptor in human renal allografts (1993) (27)
Influenza Virus Infection Elicits Protective Antibodies and T Cells Specific for Host Cell Antigens Also Expressed as Tumor-Associated Antigens: A New View of Cancer Immunosurveillance (2013) (27)
Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas (2016) (27)
Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen (2012) (27)
T CELL RECEPTOR Vβ GENE USAGE IN HLA‐DR1‐REACTIVE HUMAN T CELL POPULATIONS: THE PREDOMINANCE OF Vβ8 (1992) (26)
Retroviral expression of MUC-1 human tumor antigen with intact repeat structure and capacity to elicit immunity in vivo. (1998) (25)
Complex of MUC1, CIN85 and Cbl in Colon Cancer Progression and Metastasis (2015) (25)
Cancer vaccines: a promising cancer therapy against all odds. (2007) (23)
Preventive immunization of aged and juvenile non-human primates to beta-amyloid (2012) (23)
Antigen-specific, MHC-unrestricted T cells (1992) (22)
Biochemical characterization of the soluble form of tumor antigen MUC1 isolated from sera and ascites fluid of breast and pancreatic cancer patients. (2001) (22)
Multiple HLA-DR antigens: detection with monoclonal antibodies and translation in vitro. (1982) (22)
Evaluation of Anticyclin B1 Serum Antibody as a Diagnostic and Prognostic Biomarker for Lung Cancer (2005) (22)
Preventing cancer by targeting abnormally expressed self‐antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas (2013) (21)
Variables affecting the T cell receptor V beta repertoire heterogeneity of T cells infiltrating human renal allografts. (1993) (21)
Long-term culture and characterization of alloreactive T-cell infiltrates from renal needle biopsies. (1985) (20)
Human allograft-derived T-cell lines: donor class I- and class II-directed cytotoxicity and repertoire stability in sequential biopsies. (1988) (18)
Effector T-cell repertoire selection in human allograft rejection. (1989) (18)
A decade in the life of tumor immunology. (2001) (18)
Molecular origins of cancer (2008) (17)
A new strategy for tumor antigen discovery based on in vitro priming of naive T cells with dendritic cells. (2001) (17)
Tumor-associated MUC 1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC 1 peptide epitopes in MUC 1 transgenic mice (2009) (17)
Mucins in gastrointestinal cancers. (2003) (17)
Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-κB p65 and EzH2, in colitis-associated cancer (2017) (17)
Immunological Weapons Acquired Early in Life Win Battles with Cancer Late in Life (2008) (16)
Cytofluorometric isolation of I937, an Ia antigen-bearing variant of the Ia-negative human monocytic cell line U937. (1985) (16)
Migration of cultured chimpanzee dendritic cells following intravenous and subcutaneous injection. (1997) (15)
Categories of Tumor Antigens (2003) (14)
Recombinant epithelial cell mucin (MUC-1) expressed in baculovirus resembles antigenically tumor associated mucin, target for cancer immunotherapy. (1995) (14)
T cell receptor (TCR) repertoire in alloimmune responses. (1996) (13)
Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines (2004) (12)
T cells receptor beta-chain repertoires are nonrandomly selected in responses to HLA-DR1. (1996) (12)
Tumor immunology at the service of cancer immunotherapy. (2004) (12)
T-cell receptor gene usage and expression in renal allograft-derived T-cell lines. (1990) (12)
Antigen Choice Determines Vaccine-Induced Generation of Immunogenic versus Tolerogenic Dendritic Cells That Are Marked by Differential Expression of Pancreatic Enzymes (2013) (11)
H-2 antigen expression: Loss in vitro, restoration in vivo, and correlation with cell-mediated cytotoxicity in a mouse lymphoma cell line (1978) (11)
Human papillomavirus vaccine for cancer prevention. (2009) (11)
Functional and molecular analysis of T cell receptors used by pancreatic- and breast tumor- (mucin-) specific cytotoxic T cells. (1998) (11)
Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy (2009) (11)
Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments (2013) (10)
Retroviral transduction of protein kinase C-gamma into cytotoxic T lymphocyte clones leads to immortalization with retention of specific function. (1991) (10)
EXPRESSION OF TUMOR-ASSOCIATED EPITOPES BY EBV-IMMORTALIZED B CELLS AND BURKITTʼS LYMPHOMAS TRANSFECTED WITH EPITHELIAL MUCIN (1992) (10)
Characterization of human myelomonocytic antigens using monoclonal antibodies. (1983) (10)
Antigens expressed on NIH 3T3 cells following transformation with DNA from human pancreatic tumor. (1986) (9)
Myeloid derived suppressor cells in cancer, premalignancy and inflammation: A roadmap to cancer immunoprevention (2020) (9)
Immunity against Cyclin B1 Tumor Antigen Delays Development of Spontaneous Cyclin B1‐Positive Tumors in p53−/− Mice (2009) (9)
Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo. (1994) (9)
In vitro and in vivo human T cell repertoire in kidney allograft rejection. (1988) (9)
Screening of Anti-MUC1 Antibodies for Reactivity with Native (Ascites) and Recombinant (Baculovirus) MUC1 and for Blocking MUC1 Specific Cytotoxic T-Lymphocytes (1997) (8)
In vitro analysis of the human antiporcine T-cell repertoire. (1992) (8)
Tumor-specific immune responses and opportunities for tumor vaccines. (1994) (8)
Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention (2020) (8)
Cancer-Testis (CT) Antigens (2003) (8)
A human suppressor T-cell factor that inhibits T-cell replication by interaction with the IgM-Fc receptor (CD7). (1989) (8)
Tumor immunology top 10 list (2008) (8)
Human Ia beta chains and the invariant chain share a common antigenic determinant (1983) (8)
Protein kinase C gamma expression mimics phorbol ester-induced transcriptional activation of a murine VL30 enhancer element. (1991) (7)
Incidence rate of breast cancer in young women. (2013) (7)
Human renal allograft infiltrating T cells: phenotype-function correlation and clonal heterogeneity. (1988) (7)
The FDA Guidance on Therapeutic Cancer Vaccines: The Need for Revision to Include Preventive Cancer Vaccines or for a New Guidance Dedicated to Them (2015) (7)
A phase 1B study of a MUC1 pulsed autologous dendritic cell (DC) vaccine as adjuvant therapy in patients (Pts) with resected pancreatic or biliary tumors (2004) (7)
Tn-MUC 1 DC Vaccination of Rhesus Macaques and a Phase I / II Trial in Patients with Non-Metastatic Castrate Resistant Prostate Cancer (2016) (7)
Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines (2009) (7)
The effects of sialoglycoconjugates on adenovirus-mediated gene transfer to epithelial cells in vitro and in human airway xenografts. (1997) (7)
Evidence that drug-resistant alloreactive T cells may contribute to human graft rejection. (1990) (6)
Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention. (2020) (6)
Advances in immuno-oncology. Foreword. (2012) (6)
Mimic 1 of MUC1 (1998) (6)
Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance. (2012) (6)
Global Inhibition of DC Priming Capacity in the Spleen of Self-Antigen Vaccinated Mice Requires IL-10 (2014) (6)
Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting (2020) (6)
Characterization of T cells expressing the gamma/delta antigen receptor in human renal allografts. (1993) (6)
Altered Expression of the Epithelial Mucin MUC1 Accompanies Endoscopic Recurrence of Postoperative Crohn’s Disease (2020) (6)
Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells (1996) (6)
Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells (2013) (5)
Recombinant human tumor antigen MUC1 expressed in insect cells: structure and immunogenicity. (2001) (5)
Human Tumor Immunology at the Molecular Divide (2007) (5)
Relationships among renal allograft biopsy infiltrates, growth of T cell lines, and irreversible rejection. (1988) (5)
Editorial: Myeloid Derived Suppressor Cells as Disease Modulators (2020) (5)
Analysis of the frequency of MHC-unrestricted MUC1-specific cytotoxic T-cells in peripheral blood by limiting dilution assay. (2000) (5)
History of tumour vaccines and novel approaches for preventive cancer vaccines. (2004) (5)
Cancer Immunotherapy: Challenges and Opportunities (2007) (5)
A phase 1B study of a MUC1 pulsed autologous dendritic cell (DC) vaccine as adjuvant therapy in patients (Pts) with resected pancreatic or biliary tumors. (2004) (4)
Wild-Type Th Cells Corrected by Adoptive Transfer of Regulatory Cell Imbalance That Can Be MUC 1-Transgenic Mice Results from a Th / T Antigen-Specific Immunity in Lack of Effective MUC 1 Tumor (2007) (4)
Expression of MUC1 in insect cells using recombinant baculovirus. (2000) (4)
Abstract CT236: Randomized, double-blind, placebo-controlled trial of preventative MUC1 vaccine in patients with newly diagnosed advanced adenomas: Results from one-year booster (2019) (4)
Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions. (2020) (4)
Assessing the important effector mechanisms in the immune response against cancer. (2001) (4)
Novel Mechanisms Underlying the Immediate and Transient Global Tolerization of Splenic Dendritic Cells after Vaccination with a Self-Antigen (2014) (4)
Cancer vaccines: the state of the art. (2010) (4)
Cloning and Expression of Human Membrane-Bound and Soluble Engineered T Cell Receptors for Immunotherapy (2006) (3)
Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Introduction (1998) (3)
Cancer vaccines (2022) (3)
Antigen Tumor-Specific Peptide Epitope on the Epithelial the MHC-Unrestricted TCR Recognition of a Intercellular and Intracellular Events Following (1998) (3)
Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study (2015) (3)
Therapeutic and Prophylactic Cancer Vaccines (2016) (3)
MUC1 Mucin as a Tumor Antigen in Breast Cancer (1999) (3)
Innate and adaptive immunity in lung cancer. (2006) (3)
Moniliformis moniliformis (Acanthocephala: Moniliformidae) in the cockroach Periplaneta americana in Puerto Rico (1974) (3)
Abstract 5510: Immunogenicity of the MUC1/Poly-ICLC vaccine in individuals with the history of advanced colorectal adenoma (2011) (2)
Abstract A16: A phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients (2012) (2)
Abstract CT222: A pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer (2019) (2)
Pancreatic tumor antigens: diagnostic markers and targets for immunotherapy. (1992) (2)
MUC1 expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with NF- κ B p65 and binding to cytokine promoters: importance of the extracellular domain (2011) (2)
Functional and molecular analysis of T cell receptors used by pancreatic- and breast tumor- (Mucin-) specific cytotoxic T cells : T cell response to tumors (1998) (2)
Abstract 492: Identification of a novel complex MUC1/CIN85 involved in invasion and migration of breast cancer cells (2012) (2)
Characteristics of a human liver allograft--derived T-cell line that exhibits suppressor activity. (1989) (2)
T cell receptor V beta gene usage in HLA-DR1-reactive human T cell populations. The predominance of V beta 8. (1992) (2)
Myeloid derived suppressor cells (MDSC) and anti-MUC1 immunosurveillance in pre-malignancy and cancer (2018) (1)
Abstract 3151: Muc1/Cin85 complex is a new molecular target for control of cancer invasion and metastasis (2014) (1)
Antigen-specific Treg and IL-10 influence DC immunogenicity hours following vaccination with a self versus a foreign antigen (P4232) (2013) (1)
MUC1 mucin as a target for immunotherapy of cancer: Muc1 based immunotherapeutic strategies (2001) (1)
Epithelial Tumor Antigens (2003) (1)
T-Cell Function in Advanced Cancer Patients Peroxide Are the Underlying Mechanism of Suppression of Activated Granulocytes and Granulocyte-derived Hydrogen Updated (2001) (1)
Abstract 2886: Epigenetic regulation of MUC1 in NF-kB target gene expression of pro-inflammatory cytokines in colon cancer (2015) (1)
Introduction: Report on the Keystone Symposium (1993) (1)
Bridging the innate and adaptive immune responses against cancer: 95th AACR meeting 2004 (2005) (1)
Cancer vaccines: The state of the art. (2010) (1)
Tumor Antigens as Modulators of the Tumor Microenvironment (2008) (1)
Introduction to The Renaissance of Cancer Immunotherapy (2013) (1)
Two Alpha Chains and Three Beta Chains of Human Ia Antigens (1983) (1)
LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors (2022) (1)
Cancer vaccines: emphasis on pediatric cancers. (2010) (1)
Inflammation and Cancer (2017) (1)
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma (2022) (1)
Introduction to the special issue: Tumor antigens in the time of the coronavirus pandemic (2020) (1)
Cellular immunity and the immunotherapy of cancer : proceedings of a Cetus, Immunex, and Triton Biosciences-UCLA Symposia Colloquium held at Park City, Utah, January 27-February 3, 1990 (1990) (1)
Function and specificity of suppressor T-cells and factors derived from a human renal allograft recipient. (1989) (1)
Identification of Cell Surface Molecules That Determine the Macrophage Activation Threshold Associated With an Early Stage of Malignant Transformation (2021) (1)
Abstract LB-305: Randomized, double-blind, placebo-controlled immunoprevention trial with MUC1 vaccine in patients with newly diagnosed advanced adenomas (2018) (1)
MUC1 modulates NF-kB-dependent gene expression of pro-inflammatory cytokines by altering their epigenetic regulation (TUM7P.944) (2014) (1)
Preventive immunization of aged and juvenile non-human primates to beta-amyloid (2012) (1)
Differential glycosylation of MUC 1 in tumors and transfected epithelial and lymphoblastoid cell lines (1)
Enzymesby Differential Expression of Pancreatic Tolerogenic Dendritic Cells That Are Marked Generation of Immunogenic versus Antigen Choice Determines Vaccine-Induced (2013) (1)
A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa). (2011) (1)
Activating and tolerizing signaling “fingerprint” in T cells responding to DC/tumor MUC1 vaccine (156.23) (2011) (0)
Abstract 6537: Single cell transcriptomics uncovers cellular and molecular differences in PBMCs of responders and non-responders to the MUC1 cancer vaccine given in the preventative setting (2023) (0)
T Cells + MUC 1 Primes Human CD 4 Naturally Processed Class II Epitope from the Tumor Antigen Updated (2006) (0)
Abstract CN08-04: Testing cancer vaccines in the setting of premalignant disease: State of immunity and determinants of response (2011) (0)
Immunology in Pittsburgh (2006) (0)
Advances in Brief Humoral Immunity against a Tandem Repeat Epitope of Human Mucin MUC-1 in Sera from Breast , Pancreatic , and Colon Cancer Patients ' (2006) (0)
Tumor-resident macrophages modulate intestinal barrier function through sialylation of Mucin 1 in IBD and colitis-associated cancer. (2018) (0)
Use of intrauterine device and ovarian cancer risk (2006) (0)
Regulation of expression of “pancreatic” proteases in dendritic cells: a novel mechanism of peripheral tolerance (100.34) (2011) (0)
Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic DC (P1104) (2013) (0)
T.31. Antigen Dose Over-rides DC Phenotype in the Control of CD4 + Regulatory T Cell Induction (2009) (0)
Cytotoxic T-Lymphocytes Derived from Patients with Breast Adenocarcinoma Recognize an Epifope Present on the Protein Core of a Mucin Molecule Preferentially Expressed by Malignant Cells1 (2006) (0)
Human anti-MUC1 antibodies elicited by a prophylactic cancer vaccine for CAR T cell immunotherapy. (2016) (0)
The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021 (2022) (0)
Abstract PR002: A pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer (2023) (0)
Dendritic Cells after Vaccination with a and Transient Global Tolerization of Splenic Novel Mechanisms Underlying the Immediate (2015) (0)
Immunity to MUC1 in pancreatic and breast cancer (2007) (0)
Antigen dose over-rides DC phenotype in the control of CD4+ regulatory T cell induction through reduced Akt/mTOR signaling (89.30) (2009) (0)
From mom to prof: “Make an effort” (2013) (0)
Hybridoma monoclonal antibodies in the analysis fo human cell surface antigens (1981) (0)
DivideHuman Tumor Immunology at the Molecular (2007) (0)
Mo1987 - Randomized, Double-Blind, Placebo-Controlled Immunoprevention Trial with MUC1 Vaccine in Patients with Newly Diagnosed Advanced Adenomas (2018) (0)
Abstract 5643: TCRβ repertoire analysis from a prophylactic MUC1 cancer vaccine trial (2018) (0)
Abstract 1763: Acute but not chronic LCMV infection generates immunity against abnormally expressed self-antigens on infected and tumor cells and protects against lung and lymphoid cancers in mice (2021) (0)
Cloning and characterization of human pancreatic adenocarcinoma genes (1985) (0)
Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Antigen Processing and Presentation Chimpanzee Dendritic Cells Derived In Vitro from Blood Monocytes and Pulsed with Antigen Elicit Specific Immune Responses In Vivo (1998) (0)
Preface to the symposium in writing on therapeutic cancer vaccines (1996) (0)
Abstract LB179: Patient-derived, vaccine-elicited, anti-MUC1 antibodies directly target tumor cells for elimination via multiple immune mechanisms (2022) (0)
DC enzymes as early biomarkers of an effective vaccine (46.7) (2012) (0)
Multidisciplinary Thoracic Cancers Symposium ( December 2-4 , 2021 ) (2021) (0)
Viral infection induces immune responses to many self-proteins, some of which are known tumor associated antigens (53.23) (2012) (0)
Th 1 Type Immunity and Elicits Maturation but Does Not Promote Chemotactic for Immature Dendritic Cells Human Tumor Antigen MUC 1 Is (2005) (0)
The Influence of Randomized Controlled Cancer Chemoprevention Trials on the Evolution of Regulatory Assessments (2011) (0)
Cytotoxic T-Lymphocytes Derived from Patients with Breast Adenocarcinoma Recognize an Epifope Present on the Protein Core of a Mucin Molecule Preferentially Expressed by Malignant Cells 1 (2006) (0)
MUC1 promotes an inflammatory microenvironment aggravating colitis-associated tumorigenesis in mice through up-regulation of pro-inflammatory cytokines. (2016) (0)
Highlights from the literature (2019) (0)
Overexpression and Hypoglycosylation of MUC1 is Associated with Endoscopic Recurrence of Post-Operative Crohn’s Disease (2017) (0)
Influenza virus infection elicits antibodies and T cells to host cell antigens previously identified as tumor associated antigens: a new view of cancer immunosurveillance (P2131) (2013) (0)
Identification of a macrophage activation threshold associated with malignant transformation and the sensing of candidate “danger signals” (2021) (0)
Programming the immune system through childhood infections: MUC1 tumor-associated antigen (TAA) as a disease-associated antigen (DAA) (2014) (0)
Dendritic Cells in Human Cancer (2008) (0)
Tumor-associated antigen MUC1 contains self epitopes subject to self-tolerance and tumor-associated "foreign" epitopes that elicit effective immunity: important distinction for cancer vaccines (2009) (0)
Cell Cycle Regulatory Proteins as Tumor Antigens (2003) (0)
Anti-MUC 1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer : A Feasibility Study (2015) (0)
Multiple HLA-DR antigens : Detection with monoclonal antibodies and translation . inovitro ( 13 chain-reactive antibody / Xenops oocytes / immunoprecipitation / one-and two-dimensional electrophoresis ) (2003) (0)
Abstract 3747: msa2 biotin-binding CAR combined with biotinylated tumor-specific antibodies or DNA aptamers for universal cancer immunotherapy (2017) (0)
Tumor immunity in mice reconstituted with BM cells engineered to express single chain T cell receptor specific for the tumor antigen MUC1. (2004) (0)
Isolation and Properties of a Human Pancreatic Adenocarcinoma-associated Antigen, DU-PAN-21 (2006) (0)
Abstract 2875: Evidence of immunosuppression in patients with breast ductal carcinoma in situ (2023) (0)
Inflammation-induced tumor antigen expression on epithelial cells reveals the mechanism of their generation and provides a system for identification of new tumor targets (2020) (0)
Comprar The Renaissance of Cancer Immunotherapy: The 7th International Cancer Vaccine Symposium | Olivera J. Finn | 978-1-57331-895-2 | Wiley (2013) (0)
Vaccines based on self (tumor) antigens: Accomplishments and challenges. (2006) (0)
Abstract 2509: Human anti-MUC1 antibodies elicited by a prophylactic cancer vaccine for mAb and CAR-modified T cell immunotherapies (2015) (0)
Application of Tumor Antigens for Clinical Immunotherapy (2003) (0)
University of Pittsburgh Graduate Training Program in Breast Cancer Biology and Therapy (2000) (0)
Abstract A66: IL-33 promotes CD8 T cell effector function and has a potent antitumor activity in vivo. (2013) (0)
Highlights from the literature (2013) (0)
Abnormal MUC1 Expression in Post-operative Crohnʼs Disease Recurrence: 673 (2016) (0)
A human suppressor T cell factor inhibits in vitro T cell proliferation by interaction with the CD7 receptor (1988) (0)
T CELL RECEPTOR Vβ GENE USAGE IN ALLOGRAFT‐DERIVED CELL LINES ANALYZED BY A POLYMERASE CHAIN REACTION TECHNIQUE1 (1992) (0)
Functional and Molecular Analysis of T Cell Receptors Used by Pancreatic- and Breast Tumor- (Much-) Specific Cytotoxic T Cells (2006) (0)
MUC-1 mucin made more immunogenic by presentation on dendritic cells (1998) (0)
Cancer vaccines :sixth international symposium (2009) (0)
MUC1 Primes Human CD4+ T Cells Naturally Processed Class II Epitope from the Tumor Antigen (2013) (0)
RENAL ALLOGRAFT‐INFIL TRATING LYMPHOCYTES A PROSPECTIVE ANALYSIS OF IN VITRO GROWTH CHARACTERISTICS AND CLINICAL RELEVANCE (1992) (0)
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020 (2021) (0)
Transcriptional regulation of proteolytic enzymes in dendritic cells by effector versus regulatory T cells: a new mechanism of maintaining peripheral tolerance (52.15) (2011) (0)
The cross-talk between infiltrating macrophages and inflamed or malignant colonic epithelium promotes overexpression of ST6GALNAC1 and epithelial MUC1 tumor form MUC1-sTn (2019) (0)
Abstract PR02: MUC1 vaccine for colon cancer prevention: Microarray and bioinformatic analysis of pre-vaccination gene signatures distinguishing responders from non-responders (2015) (0)
Immunization with “self” peptide induces a novel phenotype of splenic dendritic cells contributing to peripheral tolerance (48.10) (2012) (0)
Is nipple aspirate fluid (NAF) a reliable source to identify biomarkers in breast cancer? A feasibility study. (2015) (0)
Evaluating serum anti-cyclin B1 antibodies as a biomarker for prevalent, early lung cancer in a population at high-risk for lung cancer (2006) (0)
Covalent adaptor synNotch and chimeric antigen receptors (CARs) for programmable antigen targeting (2019) (0)
Dorian Gray mice exposed (1993) (0)
Cloning of human pancreatic adenocarcinoma genes (1985) (0)
Introduction: Report on the Keystone Symposium Cellular Immunity and the Immunotherapy of Cancer II (1993) (0)
Abstract 4153: Abnormal expression of MUC1 mucin on colon epithelia stimulates production of pro-inflammatory cytokines promoting colitis-associated colon cancer in a murine model (2016) (0)
Ovarian tumour reactive cytotoxic T lymphocytes can recognize peptide determinants on polymorphic epithelial mucins Muc-1 (1995) (0)
Patient-derived, vaccine-elicited MUC1 antibodies mediate immune effector functions against cancer cells (2019) (0)
Preface: Happy 10th anniversary! (2011) (0)
Overexpression of abnormal epithelial glycoprotein MUC1 is associated with pancreatitis and other extraintestinal complications in inflammatory bowel disease (IBD) (2008) (0)
Tumor-associated antigen MUC1 contains self epitopes subject to self-tolerance and tumor-associated “foreign” epitopes that elicit effective immunity: important distinction for cancer vaccines (41.60) (2009) (0)
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020 (2021) (0)
Exposure to abnormal self antigens during non-malignant events may provide immunological defense against tumors (165.15) (2011) (0)
Martin A. “Mac” Cheever, MD: In Memoriam (1944–2021) (2021) (0)
Editorial: Cancer Prevention: Targeting Premalignant Epithelial Neoplasms in the Era of Cancer Immunotherapy and Vaccines (2022) (0)
The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021 (2022) (0)
Abstract 4126: Validation of hypoglycosylated MUC1-CIN85 protein-protein interaction as a new therapeutic target for prevention of cancer invasion and metastasis (2017) (0)
All in one: VLP‐MUC1 vaccine for prevention and treatment of epithelial tumors (2008) (0)
Idiotypes as Tumor Antigens (2003) (0)
P-296 Post-operative Crohn's Disease Endoscopic Recurrence Is Associated with Aberrant MUC1 Expression (2017) (0)
P-491 Immune response against cyclin B1 as a tumor antigen in patients with lung cancer and benign lung disease (2003) (0)
IL-33 promotes type 1 cell-mediated immunity and has a potent antitumor function (46.25) (2012) (0)
Abstract 5380: Prophylactic MUC1/Poly-ICLC vaccine in individuals with the history of advanced colorectal adenoma (2012) (0)
SNP in exon 2 of the MUC1 gene generates a candidate minor histocompatibility antigen through alternative splicing (2008) (0)
Human anti-MUC1 antibodies elicited by a prophylactic cancer vaccine for mAb and CAR-modified T cell immunotherapies (VAC11P.1004) (2014) (0)
Abstract SY17-03: Tumor-associated antigen MUC1 vaccine for colon cancer prevention (2021) (0)
Tolerance and immunity to tumor‐associated antigen MUC1 in MUC1.Tg mice (2008) (0)
Involvement of regulatory T cells and Th17 cells in ovarian endometriosis and ovarian epithelial tumors (2008) (0)
MUC1 mucin undergoes alternative splicing in normal (activated T cells) and tumor (MCF7) cells resulting in different isoforms (2007) (0)
MUC1 Mucin Expressed no Activated T Cells has a Regulatory Function (87.17) (2007) (0)

This paper list is powered by the following services:

Other Resources About Olivera Finn

en.wikipedia.org

What Schools Are Affiliated With Olivera Finn?

Olivera Finn is affiliated with the following schools: